 |
|
 |
India |
|
|
Indian Pharmaceutical Market, The
Challenges & Opportunities
Publication Date February 2007
Publisher Espicom
Product Type Report
Pages 186
ISBN Number not applicable
Product Code ESP423
|
|
|
Summary
Espicom's in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
India has a huge population in excess of one billion people and a growing middle class with access to high quality healthcare. Conversely, in this geographically vast country plagued by natural disasters, the majority of the population is both rural and poor and western style pharmaceuticals are not even an issue for millions of people. Leading private healthcare providers are also striving to make India an international health resort, with an airport to airport concept of health tourism.
On a national level, the Indian health system is ill-equipped to cope with the rising number of elderly and the changing disease patterns, with an average of just 0.7 hospital beds and 0.6 physicians per thousand population. India faces the continuing challenge of fighting infectious diseases like malaria, tuberculosis and leprosy alongside increases in lifestyle related problems faced by the developed world, such as cancer, cardiovascular disease and diabetes.
In order to fulfil its obligations under the WTO TRIPS agreement, India was required to formally recognise pharmaceutical product patents with effect from 1st January 2005. In order to do so, the Patents Bill had to be amended, a process that was subject to lengthy delays and numerous heated debates. The Patents (Amendment) Bill 2005 was eventually pushed through both houses of the Indian parliament just before the Easter break in March 2005.
The introduction of product patents has renewed multinational interest in India and there have been a number of acquisitions of Indian companies. Recently, for example, Solvay signed a binding sale and purchase agreement for the acquisition of the Polymers Division of Gharda Chemicals. But the news is not all bad for the domestic industry. Running parallel to the opportunities for foreign acquisition, however, are the opportunities that arise for domestic companies for collaboration with foreign companies interested in capitalising on India's renowned skills and relatively low costs.
India has more US FDA approved laboratories than any other country outside the USA. A number of US companies already source pharmaceutical raw materials from India. In comparison with China, the wide use of English in commerce is mooted as an advantage to US companies, along with India's tradition as an exporting nation. India should prove to be a useful regional production base. Partnering an Indian company may also provide a good route to commercialisation in targeted markets such as Brazil or Russia, where Indian companies have an established presence. In addition, India has a large and varied patient base along with the necessary chemical and analytical skills at a comparatively low cost to make it an attractive base for clinical trials. R&D alliances are already being forged between multinationals and domestic companies.
India accounts for less than two per cent of the world market for pharmaceuticals, with an estimated market value of US$10.4 billion in 2007 at consumer prices, or around US$9 per capita. The vast majority of pharmaceuticals available in India are already off patent and generics are likely to dominate the market for the foreseeable future.
|
Content
Background Data
-
- Chichester, West Sussex, PO20 2FS, United Kingdom
- Geography
- Political Overview
- Economic Overview
- Population
- Population by States and Territories, 2001-2006
- Demographic Indicators
- Demographic Indicators, 1995-2005
- Demographic Indicators by State, 2005
- Mortality
- Major Causes of Death, Rural India 1993-1998
- Deaths from Non-Communicable Diseases, 1998
- Morbidity
- National Rural Health Mission
- Child Survival and Safe Motherhood
- Reproductive and Child Health Programme
- Woman & Child Development Project
- Universal Immunisation Programme
- Reported Incidence of Vaccine Preventable Diseases, 1985-2000
- Reducing Fertility
- Family Planning
- All India Hospitals Post-Partum Programme
- National Health Programmes for Disease Control/Eradication
- National Vector Borne Disease Control Programme
- Malaria
- Reported Malaria Incidence & Deaths, 1990-2004
- Filariasis
- Kala-azar
- Reported Kala-azar Cases & Deaths, 1996-2004
- Japanese Encephalitis
- Suspected Japanese Encephalitis Cases & Deaths, 2000-2005
- National Programme for the Control of Blindness
- National Leprosy Eradication Programme
- National Tuberculosis Control Programme
- HIV/AIDS
- National AIDS Control Programme
- Cancer
- India Background Data
- Charts
- Map of India
- Population by Age Group, 2006 (%)
- Chichester, West Sussex, PO20 2FS, United Kingdom
Healthcare System
- Organisation & Administration
- The Department of Health
- The Department of Family Welfare
- The Department of Indian Systems of Medicine & Homeopathy
- Health Insurance
- Apollo Family Health Plan
- Health Expenditure
- Health Expenditure by Source of Funds, 2001/02
- Department of Health Budget Allocations, 2004-2006
- MoHFW Health Expenditure by Scheme, 2004/05
- Hospital Services
- Hospital Resources
- Hospitals & Beds by State & Sector, 2002
- Government Hospitals/CHCs and Beds by State, 2006
- Hospitals, Dispensaries & Beds, 1991-1998
- Beds in Selected Hospitals, 2001/02
- All India Institute of Medical Sciences (AIIMS)
- Aiims Hospital Beds, 1999/2000
- Aiims Hospital Beds By Specialty, 1999/2000
- Aiims Hospital Activity, 1999/2000
- Safdarjung Hospital, New Delhi
- Safdarjung Hospital Beds by Specialty, 2003
- Dr. Ram Manohar Lohia Hospital, New Delhi
- Dr. Ram Manohar Lohia Hospital Beds by Specialty, 2000/01
- Jipmer Hospital, Pondicherry
- Jipmer Hospital Beds By Specialty, 2000
- Pgimer Nehru Hospital, Chandigarh
- Pgimer Nehru Hospital Beds By Specialty, 2001/02
- Lady Hardinge Medical College Associated Hospitals, New Delhi
- Private Hospitals and Clinics
- Apollo Hospitals Group
- Fortis Healthcare
- Max Healthcare
- Other Commercial Providers
- Ambulatory Care
- Sub-centres and Primary Health Centres, 2004-2005 (September)
- CGHS Out-patient Facilities, 31st March 2005
- First Aid and Disaster Relief
- India Healthcare System
- St. John Ambulance
- Indian Red Cross Society
- Healthcare for the Underprivileged, Scheduled Castes and Scheduled Tribes
- Healthcare Infrastructure in Tribal/Scheduled Caste Areas, 1995-2005
- Medical Care for Remote & Marginalised Tribal & Nomadic Communities
- Medical Personnel
- Doctors Registered with State Medical Councils, 1995-2004
- Registered Dental Surgeons, 1994-2004
- Registered Nursing Personnel, 1994-2004
- Healthcare Personnel in Rural Areas, 1998-2005
- Charts
- Health Expenditure by Source, 2001/02 (%)
- Department of Health Budget Allocation by Segment, 2005/06 (%)
- Chichester, West Sussex, PO20 2FS, United Kingdom
- Accessing The Pharmaceutical
- Market
Accessing The Pharmaceutical Market
- Introduction
- Regulatory Environment
- National Pharmaceuticals Policy 2006
- Pharmaceutical Registration
- Advertising
- Patent Protection & Intellectual Property Rights
- Background to Pharmaceutical Patents
- Mashelkar Committee Report, December 2006
- The Patents (Amendments) Bill, 2005
- Compulsory Licensing
- Pre- & Post-Grant Opposition
- Mailbox Applications
- Other Issues
- The Patents (Amendment) Rules 2006
- Previous Patents Act Amendments and Exclusive Marketing Rights
- Glivec/Gleevec Patent Setback for Novartis
- Pricing
- Drugs (Prices Control) Amendment Order and Second Amendment Order, 2006
- Price Reductions
- Drug Price Control Review Committee
- Distribution Channels
- Medical Stores Organisation
- Trade Fairs
- Pharma + Biotech World Expo 2007
- India Pharma 2006
- Domestic Production
- Global Sales by Leading Domestic Companies, 2005/06
- BCG Vaccine Laboratory, Chennai (Madras)
- Trade Associations
- Domestic Producers
- Alembic Ltd
- Alembic Financial Results, 2003-2006
- Aurobindo Pharma
- Aurobindo Pharma's ANDA Approvals, 2004-2007
- Aurobindo Pharma Financial Results, 2003-2006
- Biocon
- Biocon Financial Results, 2003-2006
- Blue Cross Laboratories Ltd
- India Accessing The Pharmaceutical Market
- Cipla Ltd
- Cipla Financial Results, 2003-2006
- Dr. Reddy's Laboratories Ltd
- Dr Reddy's Laboratories ANDA approvals, 2002-2006
- Dr Reddy's Financial Summary, 2003-2006
- Lupin Limited
- Lupin's ANDA approvals, 2003-2006
- Lupin Financial Results, 2003-2006
- Natco Pharma
- Natco Pharma Financial Results, 2003-2006
- Nicholas Piramal India Ltd
- NPIL Financial Results, 2003-2006
- Orchid Chemicals & Pharmaceuticals Ltd
- Orchid's Top-10 Brands
- Orchid's ANDA Approvals, 2005-2006
- Orchid Financial Results, 2003-2006
- Ranbaxy Laboratories Ltd
- Ranbaxy's Top 10 Molecules (US$ Million)
- Ranbaxy Laboratories ANDA approvals 2002-2006
- Ranbaxy Financial Results, 2003-2006
- Sun Pharmaceutical Industries Ltd
- Sun Pharma ANDA Approvals, 2006-2007
- Caraco Pharmaceutical ANDA Approvals, 2002-2006
- Sun Pharma Financial Results, 2003-2006
- Wockhardt Ltd
- Wockhardt's ANDA Approvals, 2003-2006
- Wockhardt Financial Results, 2003-2005
- Zydus Cadila
- Zydus' ANDA Approvals, 2005-2007
- Zydus Cadila Financial Results, 2003-2006
- Domestic Formulation Sales by Therapy Area, 2006
- Multinational Activity
- Actavis
- GlaxoSmithKline
- Pfizer India
- sanofi-aventis
- Research & Development
- New Millennium Indian Technology Leadership Initiative
- Indian Council of Medical Research
- Central Research Institute, Kasauli
- Central Drug Research Institute, Lucknow
- Central Council for Research in Unani Medicine
Accessing The Pharmaceutical Market
-
- Central Council for Research in Ayurveda and Siddha
- Central Council for Research in Homeopathy
- Traditional Indian Medicines
- Components
- Ayurvedic Supply
- Directory
- Government Organisations
- Trade Associations
- Charts
- Cipla Exports by Geographic Area, 2006 (%)
- Dr Reddy's Sales by Geographic Area, 2006 (%)
- Orchid API Sales by Region, 2006 (%)
- Orchid Formulations Sales by Region, 2006 (%)
- Wockhardt Sales by Region, 2005 (%)
|
|
|
